688321 微芯生物
2025/03 - 三个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-1.219-6.9635.5091.1921.508
总资产报酬率 ROA (%)-0.584-3.5502.9130.7301.213
投入资产回报率 ROIC (%)-0.642-3.9093.3360.8561.363

边际利润分析
销售毛利率 (%)85.64586.70689.12294.34194.987
营业利润率 (%)-11.461-27.13018.5353.0145.171
息税前利润/营业总收入 (%)-8.120-12.52721.5883.4184.008
净利润/营业总收入 (%)-11.805-17.4139.3922.4185.101

收益指标分析
经营活动净收益/利润总额(%)104.43580.209-201.58222.558-62.583
价值变动净收益/利润总额(%)26.37322.335290.69515.83229.661
营业外收支净额/利润总额(%)-0.002-84.572-0.055-5.388-19.676

偿债能力分析
流动比率 (X)2.3572.4012.8922.1912.174
速动比率 (X)2.2522.3102.7712.1382.122
资产负债率 (%)52.83851.36446.62045.58725.168
带息债务/全部投入资本 (%)43.90842.10134.16729.8494.267
股东权益/带息债务 (%)117.983127.070172.198209.8781,993.300
股东权益/负债合计 (%)89.25794.688114.500114.800297.323
利息保障倍数 (X)-2.430-5.7697.0496.129-12.816

营运能力分析
应收账款周转天数 (天)82.98997.360120.07389.98363.936
存货周转天数 (天)176.957181.037238.879263.140231.585